SI2887953T1 - IMPROVED DAPTOMICINE FORMATION FORMULATION - Google Patents

IMPROVED DAPTOMICINE FORMATION FORMULATION Download PDF

Info

Publication number
SI2887953T1
SI2887953T1 SI201330908T SI201330908T SI2887953T1 SI 2887953 T1 SI2887953 T1 SI 2887953T1 SI 201330908 T SI201330908 T SI 201330908T SI 201330908 T SI201330908 T SI 201330908T SI 2887953 T1 SI2887953 T1 SI 2887953T1
Authority
SI
Slovenia
Prior art keywords
daptomycin
formulation
hydrolyzate
stable
lyophilized
Prior art date
Application number
SI201330908T
Other languages
English (en)
Slovenian (sl)
Inventor
Satya Srinivas Chetlapalli
Srirama Sarveswara Rao Mandavilli
Babu Justin
Sathyanarayan Srinivas Meda
Original Assignee
Mylan Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Limited filed Critical Mylan Laboratories Limited
Publication of SI2887953T1 publication Critical patent/SI2887953T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201330908T 2012-08-23 2013-08-22 IMPROVED DAPTOMICINE FORMATION FORMULATION SI2887953T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation
EP13838871.5A EP2887953B1 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
SI2887953T1 true SI2887953T1 (en) 2018-02-28

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330908T SI2887953T1 (en) 2012-08-23 2013-08-22 IMPROVED DAPTOMICINE FORMATION FORMULATION

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN102625697A (zh) * 2009-09-01 2012-08-01 西北大学 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
PT2887953T (pt) 2018-01-10
AU2013319737A1 (en) 2015-02-05
EP2887953A4 (en) 2016-05-25
EP2887953B1 (en) 2017-10-11
EP3287138A1 (en) 2018-02-28
ES2655215T3 (es) 2018-02-19
JP2015526463A (ja) 2015-09-10
WO2014045296A2 (en) 2014-03-27
DK2887953T3 (en) 2018-01-15
NO2887953T3 (enExample) 2018-03-10
US20150216928A1 (en) 2015-08-06
CA2881121A1 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
EP2887953A2 (en) 2015-07-01
AU2018204334A1 (en) 2018-07-05
BR112015003198A2 (pt) 2017-10-10
AU2013319737B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
AU2018322769B2 (en) Daptomycin formulations
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
CN102670497A (zh) 一种稳定的s-奥拉西坦注射用制剂及其制备方法
CA2945201C (en) Vaccine compositions
BRPI0923326A2 (pt) Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto.
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
JP2015526463A5 (enExample)
DK1506214T3 (da) 6-11 bicykliske ketolidderivater
WO2009139576A3 (ko) 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
BRPI0713334A2 (pt) suspensÕes aquaosas de tmc278
NZ700182A (en) Parenteral formulations for administering macrolide antibiotics
DK2895187T1 (da) Daptomycinformuleringer og anvendelser deraf
CN101984968A (zh) 抗肿瘤剂替莫唑胺的药物制剂制备方法
WO2016098009A1 (en) Lyophilized injectable compositions of daptomycin
WO2014045296A3 (en) Improved daptomycin injectable formulation
DE60131441D1 (de) Verfahren zur formulierung antibiotischer verbindungen
US20060229262A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
CN103880930A (zh) 万古霉素类衍生物及其制备方法和药用用途
ES3041708T3 (en) Liquid pharmaceutical composition demonstrating excellent preservation efficacy
CN103212113A (zh) 万古霉素阳离子脂质体复合纳米羟基磷灰石/壳聚糖/魔芋葡苷聚糖支架的制备方法
CN101732264B (zh) 一种头孢西酮钠冻干粉针剂
WO2007020505A3 (en) Medicinal forms of phospholipid preparations and methods for their preparation
CN104352491A (zh) 一种复方阿莫西林钠脂质体药物及其制备方法
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
CN107137652A (zh) 草果油的新用途